Introduction Moxidectin is a milbemycin endectocide recently approved for the treatment of
human onchocerciasis. Onchocerciasis, earmarked for elimination of transmission, is a …

Reports of anthelmintic resistance in Ancylostoma caninum are increasing in frequency in
the United States of America (USA). In the last few years in vitro and in vivo studies …

Prevention of heartworm disease caused by Dirofilaria immitis in domestic dogs and cats
relies on a single drug class, the macrocyclic lactones (MLs). Recently, it has been …

The macrocyclic lactones (MLs) are parasiticides able to kill a wide variety of arthropods and
nematodes. They have a high margin of safety for labeled indications, and ivermectin has …

Background Dirofilaria immitis is a filarial parasite of dogs that can cause serious or fatal
cardiopulmonary disease. Three studies were conducted to evaluate the efficacy and safety …

Background Moxidectin has previously shown limited efficacy (≤ 44.4%) against confirmed
macrocyclic lactone (ML)-resistant Dirofilaria immitis strains at 3 µg/kg after single and …

The macrocyclic lactones have pharmacokinetic properties which enhance their use against
endo-and ectoparasites in animals and man. The most consistent physico-chemical feature …

The macrocyclic lactones (MLs) are one of the few classes of drug used in the control of the
human filarial infections, onchocerciasis and lymphatic filariasis, and the only one used to …

The ATP-Binding Cassette (ABC) transporters ABCB1, ABCC2 and ABCG2 are efflux
transporters that facilitate the excretion of drugs, contribute to the function of biological …

In this multicentre study, the efficacy of a spot‐on formulation containing 10% imidacloprid
and 2.5% moxidectin (Advocate®, Bayer HealthCare) was evaluated for the treatment of …